FOR INVESTORS

Disease outmatched by the science of degradation

FOR INVESTORS

Disease outmatched by the science of degradation

FOR INVESTORS

Disease outmatched by the science of degradation

Nurix is a biopharmaceutical company accelerating development of medicines based on targeted protein degradation, the next frontier to outmatch cancer and autoimmune diseases.

More About Nurix

View All

Minimum 15 minutes delayed. Source: LSEG

SEC Filings

March 27, 2026

Additional proxy soliciting materials - definitive

DEFA14A
View HTML
0001140361-26-011504.pdf
0001140361-26-011504.rtf
0001140361-26-011504.xls

March 27, 2026

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A
View HTML
0001140361-26-011492.pdf
0001140361-26-011492.rtf
0001140361-26-011492.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

March 27, 2026

An annual report to security holders

ARS
View HTML
0001140361-26-011505.pdf
0001140361-26-011505.rtf

View All

Disease outmatched by the science of degradation

Disease outmatched by the science of degradation

Disease outmatched by the science of degradation

News

Events

2026 Annual Meeting of Stockholders

44th Annual J.P. Morgan Healthcare Conference

Webcast to Discuss Data Presented at 67th American Society of Hematology (ASH) Annual Meeting

SEC Filings

Inside The Science

Advancing Our Pipeline

Learn About Us

Work at Nurix

For Investors

For Patients